Human RPL21P44 CRISPR gRNA + Cas9 in Lenti Particles
gRNA + Cas9
PExp, GEEN
Lentiviral Vector
pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro
Ampicillin
U6 Promoter
unconjugated
Stable
Catalog No. ABIN5296560
Quick Overview for Human RPL21P44 CRISPR gRNA + Cas9 in Lenti Particles (ABIN5296560)
Gene
RPL21P44
(Ribosomal Protein L21 Pseudogene 44 (RPL21P44))
Application
Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN)
Insert
gRNA + Cas9
Vector
Lentiviral Vector
Vector Backbone
pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro
Promoter
U6 Promoter, SFFV Promoter
Bacterial Resistance
Ampicillin
Expression Type
Stable, Transient
-
-
Species
- Human
-
Purpose
- Set of 3 gRNA against RPL21P44 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and Cas9 in a single vector)
-
Sequence
- Sequence available upon placing order
-
Specificity
-
GRNAs are designed for use with Cas9 Nuclease only.
Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority of cells, except ES cells or iPS cells. -
Components
- Lentiviral particles with a set of 3 gRNAs (3 x 300 μL) covering different sequences of RPL21P44
-
Selectable Marker
- Puromycin
-
Sequencing Primer
- U6 Forward Primer: 5'--TACGTCCAAGGTCGGGCAGGAAGA--3'
-
-
-
-
Application Notes
- Recommended for quality control: Restriction Enzyme Digest and Sequencing
-
Restrictions
- For Research Use only
-
-
-
Format
- Viral Particles
-
Storage
- -80 °C
-
Expiry Date
- 12 months
-
-
- RPL21P44 (Ribosomal Protein L21 Pseudogene 44 (RPL21P44))
-
Alternative Name
- RPL21P44
-
NCBI Accession
- NM_001011538
Target
-
You are here:
